Literature DB >> 20503256

Does abnormal insulin action or insulin secretion explain the increase in prevalence of impaired glucose metabolism with age in populations of different ethnicities?

F Ning1, Q Qiao, J Tuomilehto, N Hammar, S Y Ho, S Söderberg, P Z Zimmet, J E Shaw, T Nakagami, V Mohan, A Ramachandran, T H Lam, S W Andersson, E D Janus, E J Boyko, W Y Fujimoto, Z C Pang.   

Abstract

BACKGROUND: Age is associated with both impaired glucose and insulin metabolism. To what extent the age-related changes in insulin resistance (IR) and beta-cell function contribute to the increase in prevalence of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) is less known, and this is investigated in this study.
METHODS: This study included 6610 men and 7664 women of different ethnic groups aged 30-69 years. IR and beta-cell function were examined by the homeostasis model assessment of insulin resistance (HOMA-IR) and homeostasis model assessment of beta-cell function (HOMA-B). Odds ratios (ORs) and 95% confidence intervals (95% CIs) were estimated using logistic regression analysis adjusting for body mass index and study.
RESULTS: In Chinese men, the ORs (95% CIs) for IFG were 2.69 (1.70, 4.26), 2.51 (1.49, 4.21) and 2.89 (1.68, 4.97), respectively, in age groups of 40-49, 50-59 and 60-69 years compared with 30-39 years (p < 0.001 for trend); the corresponding figures for IGT were 1.73 (1.25, 2.38), 2.54 (1.78, 3.63) and 3.57 (2.46, 5.19) (p < 0.001 for trend). Similar trends for IGT were observed also in Chinese women and other ethnic groups, but not for IFG in Mauritius Indian and Creole men. Adjustment for HOMA-IR and HOMA-B reduced the ORs in all age groups of all ethnicities for both IFG and IGT, but the risk gradient between age groups remained particularly for the IGT.
CONCLUSIONS: The age-related increase in glucose intolerance may not be fully explained by the defect in HOMA-IR and HOMA-B. As HOMA-IR and HOMA-B are only surrogate measures of insulin sensitivity and insulin secretion, the results need to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20503256     DOI: 10.1002/dmrr.1078

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  5 in total

1.  Comparison of HOMA-IR, HOMA-β% and disposition index between US white men and Japanese men in Japan: the ERA JUMP study.

Authors:  Vasudha Ahuja; Takashi Kadowaki; Rhobert W Evans; Aya Kadota; Tomonori Okamura; Samar R El Khoudary; Akira Fujiyoshi; Emma J M Barinas-Mitchell; Takashi Hisamatsu; Abhishek Vishnu; Katsuyuki Miura; Hiroshi Maegawa; Aiman El-Saed; Atsunori Kashiwagi; Lewis H Kuller; Hirotsugu Ueshima; Akira Sekikawa
Journal:  Diabetologia       Date:  2014-10-15       Impact factor: 10.122

2.  Age trajectories of glycaemic traits in non-diabetic South Asian and white individuals: the Whitehall II cohort study.

Authors:  Satoyo Ikehara; Adam G Tabák; Tasnime N Akbaraly; Adam Hulmán; Mika Kivimäki; Nita G Forouhi; Hiroyasu Iso; Eric J Brunner
Journal:  Diabetologia       Date:  2014-11-28       Impact factor: 10.122

3.  The estimation of first-phase insulin secretion by using components of the metabolic syndrome in a chinese population.

Authors:  Jiunn-Diann Lin; Chun-Hsien Hsu; Yao-Jen Liang; Wei-Cheng Lian; Chang-Hsun Hsieh; Chung-Ze Wu; Dee Pei; Yen-Lin Chen
Journal:  Int J Endocrinol       Date:  2015-03-01       Impact factor: 3.257

4.  Trajectories of glycaemia, insulin sensitivity and insulin secretion in South Asian and white individuals before diagnosis of type 2 diabetes: a longitudinal analysis from the Whitehall II cohort study.

Authors:  Adam Hulman; Rebecca K Simmons; Eric J Brunner; Daniel R Witte; Kristine Færch; Dorte Vistisen; Satoyo Ikehara; Mika Kivimaki; Adam G Tabák
Journal:  Diabetologia       Date:  2017-04-13       Impact factor: 10.122

Review 5.  Emerging Evidence of Epigenetic Modifications in Vascular Complication of Diabetes.

Authors:  Madhu Khullar; Balneek Singh Cheema; Satish K Raut
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-29       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.